Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company (ATAI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company (ATAI) trades at $4.88 with AI Score 20/100 (Grade F). Atai Beckley N. Market cap: $1.80B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026ATAI stock analysis for 2026: Analysts have set a consensus price target of $10.50 for Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company, suggesting 115.2% upside from the current price of $4.88. The AI MoonshotScore is 20/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ATAI: 4/7 perspectives are bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company (ATAI) Healthcare & Pipeline Overview
Atai Beckley N.V stands at the forefront of mental health innovation, developing clinical-stage therapies aimed at addressing severe mental health disorders, leveraging a robust research framework and strategic partnerships to enhance treatment efficacy and patient outcomes.
What Is the Investment Thesis for ATAI?
Atai Beckley N.V presents a compelling investment thesis driven by its innovative approach to mental health treatment and a robust clinical pipeline. With a market capitalization of $1.80B and a gross margin of 82%, the company is well-positioned financially to support its research initiatives. The ongoing development of its proprietary compounds, alongside strategic partnerships, is expected to drive growth in the coming years. The mental health market is projected to grow significantly, driven by increasing awareness and demand for effective treatments. Atai's focus on clinical-stage development allows it to capitalize on this growing market, with potential value drivers including successful trial outcomes and regulatory approvals. However, investors should remain aware of the inherent risks associated with clinical-stage biopharmaceutical companies, including the potential for trial failures and regulatory hurdles.
Based on FMP financials and quantitative analysis
ATAI Key Highlights
- Market capitalization of $1.80B indicates strong investor interest in mental health solutions.
- Gross margin of 82% reflects high potential profitability upon commercialization of products.
- Profit margin of -19019.4% highlights the current challenges in transitioning from clinical development to market.
- Beta of 1.60 suggests higher volatility compared to the market, indicating potential risk factors.
- No dividend yield as the company reinvests earnings into research and development.
Who Are ATAI's Competitors?
ATAI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PTN Palatin Technologies, Inc. | $11.10 | -4.23% | $288.66M | — |
| AXSM Axsome Therapeutics, Inc. | $240.85 | -1.42% | $12.39B | 31 |
| SAGE Sage Therapeutics, Inc. | $8.68 | +0.00% | $544.94M | 51 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| HEWA HealthWarehouse.com, Inc. | $0.13 | +0.00% | $5.54M | 55 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATAI's Key Strengths?
- Innovative pipeline targeting unmet needs in mental health.
- Strong gross margin indicating potential for profitability.
- Strategic partnerships enhancing research capabilities.
What Are ATAI's Weaknesses?
- High negative profit margin reflecting current developmental costs.
- Limited product portfolio as a clinical-stage company.
- Dependence on successful clinical trial outcomes.
What Could Drive ATAI Stock Higher?
- Results from ongoing clinical trials for key therapeutic candidates expected in Q4 2026.
- Active partnerships with research institutions to enhance R&D capabilities.
- Continuous engagement with regulatory bodies to facilitate drug approvals.
What Are the Key Risks for ATAI?
- High dependency on successful clinical trial outcomes.
- Regulatory challenges associated with drug development.
- Market competition from established pharmaceutical companies.
What Are the Growth Opportunities for ATAI?
- Growth opportunity 1: Atai Beckley N.V is focusing on developing novel treatments for depression, a condition affecting over 264 million people globally. The market for depression treatments is projected to reach $15 billion by 2026, driven by increasing awareness and demand for effective therapies. Atai's innovative approach and clinical pipeline position it well to capture a significant share of this growing market.
- Growth opportunity 2: The global anxiety disorders treatment market is expected to grow to $12 billion by 2025, with rising prevalence rates and a shift towards personalized medicine. Atai's research into targeted therapies for anxiety disorders aligns with this trend, providing a pathway for substantial revenue growth as successful treatments are brought to market.
- Growth opportunity 3: Atai Beckley is exploring the use of psychedelic compounds in mental health treatment, a sector that has gained traction with increasing research support and regulatory interest. The psychedelic-assisted therapy market is anticipated to grow significantly, potentially reaching $6 billion by 2027, offering Atai a unique competitive advantage in a niche yet expanding field.
- Growth opportunity 4: Collaborations with academic institutions and research organizations enhance Atai's R&D capabilities, facilitating access to cutting-edge research and technology. These partnerships can expedite the development of new therapies, positioning Atai to leverage emerging scientific advancements and capitalize on market opportunities more effectively.
- Growth opportunity 5: As mental health awareness continues to rise, there is an increasing push for innovative treatment modalities. Atai's commitment to developing evidence-based therapies through rigorous clinical trials will not only enhance its credibility but also attract potential partnerships and funding opportunities, further supporting its growth trajectory.
What Opportunities Does ATAI Have?
- Growing global market for mental health treatments.
- Increasing acceptance of psychedelic therapies in mainstream medicine.
- Potential for strategic partnerships to expand research and development.
What Threats Does ATAI Face?
- Regulatory hurdles in drug approval processes.
- Intense competition from established pharmaceutical companies.
- Market volatility affecting funding and investment opportunities.
What Are ATAI's Competitive Advantages?
- Strong focus on clinical-stage development differentiates Atai from competitors.
- Partnerships with leading research institutions enhance R&D capabilities.
- Innovative approach to mental health treatment positions Atai as a leader in the sector.
What Does ATAI Do?
Atai Beckley N.V is a clinical-stage biopharmaceutical company founded in June 2018 by Christian Angermayer, Florian Brand, Srinivas Rao, and Lars Christian Wilde. Headquartered in Amstelveen, Netherlands, Atai focuses on developing innovative treatments for mental health disorders, an area that has historically been underfunded and overlooked. The company’s mission is to transform the treatment landscape for mental health conditions by utilizing a combination of novel compounds and established therapies. Atai is committed to addressing significant unmet needs in mental health, with a portfolio of proprietary and partnered programs that target various psychiatric conditions. The company's research and development efforts are grounded in a scientific approach, with a strong emphasis on clinical trials to validate the efficacy and safety of its products. Atai Beckley operates in a challenging but promising environment, where the demand for effective mental health treatments is rising due to increasing awareness and prevalence of mental health issues globally. The company’s strategic partnerships and collaborations with leading research institutions enhance its capabilities and accelerate the development of its therapeutic candidates. As a clinical-stage company, Atai is focused on advancing its pipeline towards commercialization, aiming to bring transformative therapies to market that can significantly improve the quality of life for individuals suffering from mental health disorders.
What Products and Services Does ATAI Offer?
- Develop innovative treatments for mental health disorders.
- Conduct clinical trials to validate the efficacy and safety of their products.
- Collaborate with academic institutions for research and development.
- Focus on proprietary and partnered programs targeting psychiatric conditions.
- Address significant unmet needs in the mental health treatment landscape.
- Utilize a scientific approach to advance their therapeutic pipeline.
How Does ATAI Make Money?
- Generate revenue through the commercialization of successful therapeutic products.
- Collaborate with partners to share research costs and development risks.
- Leverage intellectual property and licensing agreements for additional revenue streams.
What Industry Does ATAI Operate In?
The mental health pharmaceuticals industry is experiencing significant growth, driven by increasing recognition of mental health disorders and a rising demand for effective treatment options. The global mental health market is projected to reach approximately $240 billion by 2026, with a compound annual growth rate (CAGR) of around 7%. Within this landscape, Atai Beckley N.V is positioned as a key player, focusing on innovative therapies that address unmet needs. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms, each vying for market share in a sector that is rapidly evolving due to advancements in research and technology. Atai's unique focus on clinical-stage development allows it to differentiate itself from competitors by targeting specific mental health conditions with tailored therapeutic approaches.
Who Are ATAI's Key Customers?
- Healthcare providers seeking effective mental health treatments.
- Patients suffering from mental health disorders looking for innovative therapies.
- Research institutions interested in collaboration and development of new treatments.
Net buyingInsider Activity
The most recent 10 insider filings for Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company break down as 1 sales and 9 purchases. On net that is roughly 8.6M shares acquired (about $2.1M) — insiders putting money in tends to read as conviction.
Quarterly Financial Performance: Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company
Revenue for Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company came in at $954K during Q1 2026, a 10.5% contraction versus the preceding quarter. The company recorded a net loss of $29.8M, with diluted EPS of $-0.13. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ATAI averaged $-0.75 in diluted EPS.
ATAI Valuation & Market Position
With a $1.80B market cap, Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company sits in the small-cap segment of the market. Relative to its peer group, ATAI's quantitative score of 20/100 is below the peer average of 51/100.
Key Financial Metrics
Its free cash flow yield is -8.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.02 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -77.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.77 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company revenue of about $1.5M for fiscal 2026, with EPS near $-0.43. The estimate reflects 9 contributing analysts.
Company Profile
Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Amstelveen, NL. The company is led by CEO Srinivas G. Rao. ATAI has traded publicly since 2021.
ATAI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- ATAI's focus on mental health is timely, given increasing awareness and acceptance of these conditions. This could drive long-term demand for their treatments.
- Recent insider buying activity suggests confidence from those closest to the company's operations and future prospects.
- Positive community sentiment indicates growing belief in ATAI's mission and potential impact on the mental health landscape.
- The company's clinical-stage status implies potential for significant breakthroughs, offering substantial upside if trials are successful.
Bear Case
- The biopharmaceutical industry is inherently risky, with high failure rates in clinical trials. ATAI's pipeline faces the same challenges.
- Negative community sentiment could reflect concerns about the company's strategy, competition, or perceived execution risks.
- Market perception of biotech companies can be volatile, especially in the current economic climate, impacting ATAI's stock performance.
- The company's focus on novel treatments means navigating complex regulatory pathways, which could lead to delays or rejections.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $953,999 | -$30M | -$0.13 |
| Q4 2025 | $1M | -$545M | -$2.45 |
| Q3 2025 | $749,000 | -$61M | -$0.28 |
| Q2 2025 | $719,000 | -$28M | -$0.14 |
Based on FMP financials and quantitative analysis
ATAI Latest News
-
Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003’s Phase 3 Readiness
Insider Monkey · Jun 17, 2026
-
Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003’s Phase 3 Readiness
Yahoo! Finance: ATAI News · Jun 17, 2026
-
Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why
Yahoo! Finance: ATAI News · Jun 16, 2026
-
Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why
Insider Monkey · Jun 16, 2026
ATAI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATAI.
Price Targets
Consensus target: $10.50
ATAI MoonshotScore
What does this score mean?
The MoonshotScore rates ATAI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003’s Phase 3 Readiness
Why AtaiBeckley (ATAI) Is Building Its Valuation Case Around BPL-003’s Phase 3 Readiness
Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why
Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why
Leadership: Srinivas G. Rao
CEO
Srinivas G. Rao has extensive experience in the biopharmaceutical industry, with a strong background in clinical development and strategic management. He holds a medical degree and has previously held leadership positions in various healthcare organizations, focusing on drug development and commercialization strategies.
Track Record: Under Rao's leadership, Atai has advanced its clinical pipeline and established key partnerships, contributing to the company's growth and positioning within the mental health sector.
What Investors Ask About Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company (ATAI) — Healthcare
What does Atai Beckley N.V do?
Atai Beckley N.V is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders. The company engages in rigorous clinical trials to validate the efficacy and safety of its products, addressing significant unmet needs in the mental health treatment landscape.
What are the main risks for ATAI?
Atai Beckley N.V faces several risks inherent to the biopharmaceutical industry, including high dependency on successful clinical trial outcomes, which can significantly impact the company's future. Additionally, regulatory challenges can delay or hinder drug approvals, while intense market competition from established pharmaceutical companies poses a threat to Atai's market positioning.
How does Atai Beckley N.V manage patent expiration risks?
Atai Beckley N.V actively manages patent expiration risks by focusing on developing a robust pipeline of innovative therapies that can provide new revenue streams. The company also engages in lifecycle management strategies to extend the commercial viability of its products, ensuring that it remains competitive in the evolving pharmaceutical landscape.
What are the key factors to evaluate for ATAI?
Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company (ATAI) holds an AI score of 20/100 (low). Analysts target $10.50 (+115%). Not financial advice.
How frequently does ATAI data refresh on this page?
ATAI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ATAI's recent stock price performance?
Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company (ATAI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline targeting unmet needs in mental health. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATAI overvalued or undervalued right now?
Valuing Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company (ATAI) requires multiple metrics. Analysts target $10.50 (+115%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ATAI?
Before investing in Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company (ATAI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All data is based on the latest available information and may be subject to change.